Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
Date:4/6/2009

NEW YORK, April 6 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. (NYSE Amex: CUR). The full 56-page report can be found at www.crystalra.com.

Neuralstem, Inc. ("Neuralstem" or "the Company") is a biotherapeutics company using a patented process to grow neural stem cells to treat central nervous system (CNS) diseases. The neurodegenerative conditions that the Company targets are incurable and are usually associated with severe side effects, such as muscle atrophy, partial or complete paralysis, or death. Neuralstem's proprietary Human Neural Stem Cell technology isolates stem cells from CNS tissue of the developing human brain and spinal cord and expands these cells in the laboratory for up to 60 doublings. By amplifying the natural ability of fetal stem cells to self-renew for long time periods, the Company creates billions of cells from each original stem cell--enabling commercial quantities from a sole donated tissue. To Neuralstem's knowledge, its technology was the first to accomplish both commercial quantities and controlled differentiation of neural stem cells into mature, physiologically relevant neurons and glia.

The initial product candidate of this therapeutic platform is a spinal cord cell line. When implanted into animal models, the cells have extended the lives of rats with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and reversed paralysis in ischemic spastic paraplegia models. In December 2008, Neuralstem filed an Investigational New Drug (IND) application for a Phase I trial of its spinal cord cells in patients with ALS, which affects roughly 30,000 people in the U.S. In February 2009, the Company received the FDA's response, which Neuralstem is now addressing. In a Phase I trial, the Company aims to study the safety and feasibility of injecting its cells directly into the spinal cords of ALS patients, where the healthy, fully functional cells are expected to replace or repair damaged and missing nerve cells.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of thirty-eight thousand, five hundred dollars and fifty thousand Warrants/Options for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the SEC.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New imaging technique reveals the atomic structure of nanocrystals
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Avantium Launches the Crystalline, a New Parallel System for Crystallization Research
4. ScinoPharm Granted US Patent for Novel Crystal Forms
5. Vermont Surgeon Implants First Accommodating Crystalens in Russia
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on The Medical House PLC
7. SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides
8. New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. Silicon photonic crystals key to optical cloaking, researchers say
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... Throughout the ... Non-GMO Project Verified label at over 13,000 stores nationwide, and industry expert David Carter ... , Now that Congress has passed the GMO labeling bill, demand for non-GMO foods ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... third-party auditor, MindFlow Design has been found to provide product development services ... Fortune 500 companies, our clients have a lot at stake when ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... Dr. Justin Zalewsky in offering LANAP® and LAPIP™ laser treatments. Drs. Hoge and ... Regeneration™ to patients, a minimally invasive and less painful option that produces real ...
(Date:9/21/2017)... ... September 21, 2017 , ... Dr. Greg Leyer, Chief Scientific Officer ... September 27th. His presentation is at 12:10pm in the Probiotics Resource Center, Mandalay Bay ... SupplySide West and discuss how probiotics have shown impressive data in areas outside the ...
Breaking Biology Technology:
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO®). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
Breaking Biology News(10 mins):